breast cancer
Obesity leads to larger, harder-to-detect tumours in breast cancer, study finds
November 21, 2017Manufacturing and Production, Research and Development Cancer, breast cancer, pharma
A study from Sweden’s Karolinska Institute has indicated that cancerous tumours in overweight women are likely to be larger and …
Breast cancer recurrence can occur up to 20 years after treatment, report shows
November 10, 2017Medical Communications, Research and Development Cancer, breast cancer, pharma, tamoxifen
New findings from the Early Breast Cancer Trialists’ Collaborative Group have demonstrated that oestrogen receptor-positive (ER-positive) breast cancer is able …
NHS England seals access deals with big pharma for breast cancer and MS
November 9, 2017Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …
17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows
November 8, 2017Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer
At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …
Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time
November 8, 2017Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …
Breakthrough AI able to identify 97% of breast cancer risk
October 18, 2017Research and Development MIT, biotech, breast cancer, drugs, pharma, pharmaceutical
Scientists at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a machine learning AI system that is able diagnose …
FDA awards Roche priority review in HER2-positive breast cancer
October 2, 2017Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma, pharmaceutical
Roche has revealed that its monoclonal antibody Perjeta (pertuzumab) has been awarded priority review by the FDA as an adjuvant …
NICE rejects AstraZeneca’s breast cancer drug Faslodex
September 1, 2017Medical Communications, Sales and Marketing AstraZeneca, Cancer, Faslodex, breast cancer, life sciences, pharma, pharmaceutical
NICE has announced its decision to not recommend AstraZeneca’s breast cancer drug Faslodex (fulvestrant) in women who have oestrogen-receptor-positive, locally …
Novartis gets EU nod for potential blockbuster breast cancer drug
August 24, 2017Sales and Marketing CDK4/6, Novartis, biotech, breast cancer, drugs, pharma, pharmaceutical
Novartis has released that it has received marketing approval from the European Commission for its drug for the treatment of …
Chemotherapy can spread breast cancer to lungs, study finds
August 9, 2017Research and Development Cancer, breast cancer, life sciences, lung cancer, pharma, pharmaceutical
Researchers at Ohio State University have discovered that, as well as forming a key part of treatment strategies to fight …
Puma Biotech’s breast cancer drug gets FDA committee nod
May 25, 2017Medical Communications, Sales and Marketing Puma Biotech, breast cancer, neratinib
Puma Biotechnology breast cancer drug that could be used to reduce the risk of disease recurrence has been boosted by …
Novartis secures first-line FDA approval in breast cancer indication
March 14, 2017Manufacturing and Production, Sales and Marketing Kisqali, Novartis, breast cancer
The FDA has approved Kisqali (ribociclib) in combination with letrozole for the first-line treatment of postmenopausal women with hormone receptor …
One in five women with breast cancer could benefit from existing therapy
March 14, 2017Manufacturing and Production, Research and Development Wellcome Trust Sanger Institute, breast cancer, parp inhibitors
A new study emerging from the Wellcome Trust Sanger Institute has discovered that there are more cases of breast cancer …
NICE rejects Pfizer’s first-in-class breast cancer drug
February 3, 2017Medical Communications, Sales and Marketing NICE, Pfizer, breast cancer
NICE has published draft guidelines which reject Pfizer’s Ibrance (palbociclib) based primarily on the cost of the drug but also …
Eisai & Clinigen to bring breast cancer drug to South Africa
December 1, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Clinigen, Eisai, South Africa, breast cancer
Eisai and Clinigen have formed a collaboration to deliver the former’s cancer treatment Halaven (eribulin) to women in South Africa …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
